Vertex shares slide on reliance on old product

4 November 2025

US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) has reported consolidated financial results for the third quarter of 2025 and refined its full year financial guidance.

Total revenue came in at $3.08 billion, an 11% increase compared to the third quarter of 2024 and ahead of the $3.06 billion figure predicted by analysts. Adjusted net income per diluted common share came in at $4.80, exceeding expectations of $4.58 and the $4.38 of a year ago.

Vertex raised the low end of its sales outlook for the year and now expects $11.9 billion to $12 billion in total, which was around what analysts expected. The prior guidance was for $11.85 billion to $12 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK